Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis purchases create global generics leader
Novartis has signed definitive agreements to acquire 100% of Hexal, Germany’s number two generics company, and a 67.7% stake in Eon Labs, a growing US generics company that
Novartis has signed definitive agreements to acquire 100% of Hexal, Germany’s number two generics company, and a 67.7% stake in Eon Labs, a growing US generics company that
After three days of hearings, an FDA advisory panel reportedly voted 17-15 to return Vioxx to the market, a closer vote than those for Celebrex and Bextra, which
Data from the questionnaire showed that, at three months, nearly 30% of psoriasis patients who were taking Enbrel (etanercept) reported that they were ‘not at all’ bothered by
The findings from the MLN2704 single ascending dose trial indicated that the novel antibody-chemotherapeutic was well tolerated and produced sustained anti-tumor activity, including one patient who achieved a
In the study, known as the P-16 study, 22 patients with androgen-dependent prostate cancer, who had undergone prior definitive surgical or radiation therapy, were enrolled and treated. Provenge
The exclusivity afforded patent, listed in the Orange Book for Imitrex (sumatriptan succinate) injection, expires on February 6, 2009. Spectrum’s abbreviated new drug application (ANDA) for sumatriptan succinate
This three-year study is the longest study of psoriasis patients receiving continuous treatment with a biologic agent. The trial, a 36-month, phase IIIb open-label study, evaluated the long-term
The study, which assessed Humira (adalimumab) in patients with moderate to severe chronic plaque psoriasis, showed that nearly 70% of patients receiving Humira 40mg every other week experienced
In the study, 54% of patients who received Amevive (alefacept) for 12 weeks achieved an ACR 20 response (a standard measure of disease improvement), or at least a
Schering-Plough and NeoGenesis have had a research collaboration since 1999 and announced that they had entered into the acquisition agreement on January 20. “This acquisition will further strengthen